Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis
Open Access
- 21 November 2001
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 1 (1) , 2
Abstract
Since the sterilising activity of new antituberculosis drugs is difficult to assess by conventional phase III studies, surrogate methods related to eventual relapse rates are required. A suitable method is suggested by a retrospective analysis of viable counts of Mycobacterium tuberculosis in 12-hr sputum collections from 122 newly diagnosed patients with pulmonary tuberculosis in Nairobi, done pretreatment and at 2, 7, 14 and 28 days. Treatment was with isoniazid and streptomycin, supplemented with either thiacetazone (SHT) or rifampicin + pyrazinamide (SHRZ). During days 0–2, a large kill due to isoniazid occurred, unrelated to treatment or HIV status; thereafter it decreased exponentially. SHRZ appeared to have greater sterilising activity than SHT during days 2–7 (p = 0.044), due to rifampicin, and during days 14–28, probably due mainly to pyrazinamide. The greatest discrimination between SHRZ and SHT treatments was found between regression estimates of kill over days 2–28 (p = 0.0005) in patients who remained positive up to 28 days with homogeneous kill rates. No associations were found between regression estimates and the age, sex, and extent of disease or cavitation. An increased kill in HIV seropositive patients, unrelated to the treatment effect, was evident during days 2–28 (p = 0.007), mainly during days 2–7. Surrogate marker studies should either be in small groups treated with monotherapy during days 2 to about 7 or as add-ons or replacements in isoniazid-containing standard regimens from days 2 to 28 in large groups.Keywords
This publication has 24 references indexed in Scilit:
- Foreword from the Co-Editor-in-ChiefTuberculosis, 2001
- Modern methods for assessing the drugs used in the chemotherapy of mycobacterial diseaseJournal of Applied Microbiology, 1996
- Assessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 MonthsAmerican Review of Respiratory Disease, 1993
- A Toolkit for Testing for Non-Normality in Complete and Censored SamplesJournal of the Royal Statistical Society: Series D (The Statistician), 1993
- Understanding the chemotherapy of tuberculosis—current problemsJournal of Antimicrobial Chemotherapy, 1992
- Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: Final reportTubercle, 1986
- The action of antituberculosis drugs in short-course chemotherapyTubercle, 1985
- CONTROLLED CLINICAL TRIAL OF FOUR SHORT-COURSE (6-MONTH) REGIMENS OF CHEMOTHERAPY FOR TREATMENT OF PULMONARY TUBERCULOSIS Third ReportThe Lancet, 1974
- A Selective Oleic Acid Albumin Agar Medium For Tubercle BacilliJournal of Medical Microbiology, 1972
- THE FATE OF MYCOBACTERIUM TUBERCULOSIS IN MOUSE TISSUES AS DETERMINED BY THE MICROBIAL ENUMERATION TECHNIQUEJournal of Experimental Medicine, 1956